tiprankstipranks
Trending News
More News >
Tempest Therapeutics Reports Q1 2025 Financial Results
PremiumCompany AnnouncementsTempest Therapeutics Reports Q1 2025 Financial Results
1M ago
Tempest Therapeutics: Navigating Financial Challenges with Promising Clinical Data and Strategic Partnerships
Premium
Ratings
Tempest Therapeutics: Navigating Financial Challenges with Promising Clinical Data and Strategic Partnerships
2M ago
Tempest Therapeutics reports Q1 EPS ($3.16), consensus ($3.29)
Premium
The Fly
Tempest Therapeutics reports Q1 EPS ($3.16), consensus ($3.29)
2M ago
Tempest Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe FlyTempest Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
3M ago
Tempest Therapeutics downgraded to Sector Perform from Outperform at Scotiabank
Premium
The Fly
Tempest Therapeutics downgraded to Sector Perform from Outperform at Scotiabank
3M ago
Tempest Therapeutics Terminates Loan Agreement with Oxford
Premium
Company Announcements
Tempest Therapeutics Terminates Loan Agreement with Oxford
3M ago
Tempest Therapeutics Advances Cancer Therapies Amid Financial Challenges
PremiumCompany AnnouncementsTempest Therapeutics Advances Cancer Therapies Amid Financial Challenges
3M ago
Tempest Therapeutics price target lowered to $7 from $13 at Scotiabank
Premium
The Fly
Tempest Therapeutics price target lowered to $7 from $13 at Scotiabank
3M ago
Tempest Therapeutics price target lowered to $16 from $47 at H.C. Wainwright
Premium
The Fly
Tempest Therapeutics price target lowered to $16 from $47 at H.C. Wainwright
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100